Justin Balko

November 17, 2016

V Foundation grants bolster cancer initiatives

Two Vanderbilt-Ingram Cancer Center (VICC) investigators have earned grant awards from The V Foundation for Cancer Research, continuing the foundation’s support for innovative cancer research initiatives at VICC.

By VUMC News and Communications
November 3, 2016

Study details rare heart risk of certain cancer therapies

By VUMC News and Communications
May 26, 2016

Precision medicine already changing cancer treatment strategies

The ability to test patients’ cancers for individual differences, mainly at the genetic level, and to make treatment decisions based on those differences is the hallmark of precision medicine, and Vanderbilt University Medical Center (VUMC) is among the leaders of this new approach to diagnosis and treatment.

By VUMC News and Communications
A smiling woman in her 50s in front of a rock wall.
April 21, 2016

Study explores how some breast cancers resist treatment

A targeted therapy for triple-negative breast cancer (TNBC), the most aggressive form of breast cancer, has shown potential promise in a recently published study. TNBC is the only type of breast cancer for which there are no currently approved targeted therapies.

By VUMC News and Communications
March 3, 2016

Melanoma response to immune therapy

Melanoma-specific expression of a certain protein identifies tumors that are more responsive to an immune therapy.

By Leigh MacMillan
December 10, 2015

VICC’s Balko named a Susan G. Komen ‘Pink Tie Guy’

Justin Balko, Pharm.D., Ph.D., assistant professor of Medicine and Cancer Biology, has been named a member of the 2016 class of Pink Tie Guys by the Greater Nashville Affiliate of Susan G. Komen, a nonprofit organization dedicated to breast cancer research and patient support.

By VUMC News and Communications
November 20, 2014

Gene mutation linked to breast cancer therapy resistance

A group of Vanderbilt-led investigators has identified a new gene mutation that may explain why some breast cancer patients do not respond to anti-hormone therapy.
By VUMC News and Communications
October 23, 2014

VICC investigators earn breast cancer grants

The grants, which total $830,000, are part of the non-profit organization’s commitment to young scientists, as well as established investigators who are searching for more effective breast cancer therapies.
By VUMC News and Communications
July 31, 2014

VICC investigators land Komen breast cancer research grants

Two Vanderbilt-Ingram Cancer Center investigators have received multi-year breast cancer research grants from the Susan G. Komen for the Cure Breast Cancer Foundation.
By VUMC News and Communications
December 7, 2012

Vanderbilt study finds diverse genetic alterations in triple-negative breast cancers

Most triple-negative breast cancer patients who were treated with chemotherapy to shrink the tumor prior to surgery still had multiple genetic mutations in their tumor cells, according to a study by Vanderbilt-Ingram Cancer Center (VICC) investigators.
By VUMC News and Communications
June 11, 2012

Vanderbilt identifies genes linked to breast cancer chemo resistance

A study led by Vanderbilt-Ingram Cancer Center investigators has identified a gene expression pattern that may explain why chemotherapy prior to surgery isn’t effective against some tumors and suggests new therapy options for patients with specific subtypes of breast cancer.
By VUMC News and Communications